pre-update Archives

Press Release

Certara Reports First Quarter 2024 Financial Result

Reiterates Full Year 2024 Financial Guidance PRINCETON, N.J.— May 7, 2024-- Certara, Inc. (Nasdaq: CERT), a…

CertaraMay 7, 2024

Guide

A Best Practice Guide to CDISC SDTM Mapping

CertaraMay 7, 2024

Publication

Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future

The article "Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future" by Karen Rowland…

CertaraMay 6, 2024

Publication

Prediction of Pediatric Pharmacokinetics for CYP3A4 Metabolized Drugs: Comparison of the Performance of Two Hepatic Ontogeny Within a Physiologically Based Pharmacokinetic Model

The rapid growth in the use of pediatric physiologically based pharmacokinetic (PBPK) models, particularly for…

CertaraMay 6, 2024

On-Demand Webinar

RAPS Sponsored Webcast: Regulatory & Tech Advances in Drug Safety Reporting

Meeting the escalating global demand for new medications requires expediting regulatory submission development. Documenting drug…

CertaraMay 3, 2024

On-Demand Webinar

Drug developers need curated clinical outcomes data to inform critical decisions

CertaraMay 3, 2024

Press Coverage

Conducting Clinical Trials in the Parallel Virtual Universe

CertaraMay 3, 2024

On-Demand Webinar

The Neuroplatform: Towards a Comprehensive Mechanistic QSP Model of Alzheimer’s Disease for Supporting Drug Discovery and Development

With over 55 million people diagnosed worldwide, Alzheimer's disease presents a significant public health challenge,…

CertaraApril 29, 2024

Publication

Multi-phase multi-layer mechanistic dermal absorption (MPML MechDermA) model to predict local and systemic exposure of drug products applied on skin

Physiologically-based pharmacokinetic models combine knowledge about physiology, drug product properties, such as physicochemical parameters, absorption,…

CertaraApril 26, 2024

Video

Explore the World of Endogenous Biomarkers with Simcyp™!

Endogenous biomarkers play a pivotal role in comprehending drug-body interactions, shaping drug development, and propelling…

CertaraApril 26, 2024

pre-update

Certara Reports First Quarter 2024 Financial Result

A Best Practice Guide to CDISC SDTM Mapping

Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future

Prediction of Pediatric Pharmacokinetics for CYP3A4 Metabolized Drugs: Comparison of the Performance of Two Hepatic Ontogeny Within a Physiologically Based Pharmacokinetic Model

RAPS Sponsored Webcast: Regulatory & Tech Advances in Drug Safety Reporting

Drug developers need curated clinical outcomes data to inform critical decisions

Conducting Clinical Trials in the Parallel Virtual Universe

The Neuroplatform: Towards a Comprehensive Mechanistic QSP Model of Alzheimer’s Disease for Supporting Drug Discovery and Development

Multi-phase multi-layer mechanistic dermal absorption (MPML MechDermA) model to predict local and systemic exposure of drug products applied on skin

Explore the World of Endogenous Biomarkers with Simcyp™!

Newsletter sign up

Quick links

Solutions

Contact